- IN₹1.30tn
- IN₹1.33tn
- IN₹68.13bn
India's Laurus Labs closes up after USFDA report for Visakhapatnam facility
Brief: Laurus Labs Received Establishment Inspection Report (Eir) From USFDA For Facility At Visakhapatnam, Andhra Pradesh
India's Laurus Labs jumps on buying additional stake in ImmunoACT
Brief: Laurus Labs Signs Investment Agreement With Immunoadoptive Cell Therapy
Brief: Laurus Labs Receives USFDA Tentative Approval Of Oral Dispersible Film (Odf) Dolutegravir 5Mg And 10Mg For Pediatric Arv Treatment
India's Laurus Labs slumps on fall in Q4 earnings
Brief: Laurus Labs Interim Dividend 1.20 Rupees Per Share
Brief: India's Laurus Labs March-Quarter Consol Net Profit Falls
Indian insurers load up on banking, consumer stocks in March- Nuvama
India's Laurus Labs hits over 2-year trough
Brief: Laurus Labs Says Usfda completed Inspection Of Facility at Andhra Pradesh
Preview: India's Divi's Laboratories hits over 2-yr low ahead of Q3 results
India's Laurus Labs sinks to 2-year low on growth uncertainty after Q3 results
India's Laurus Labs soars most in 6 months on Q3 profit jump
India's Laurus Labs posts 32% profit jump on demand for drug ingredients
Brief: India's Laurus Labs Dec-Quarter Profit Rises
Brief: Laurus Labs Received Establishment Inspection Report From USFDA
Laurus Labs rises most in over two weeks on block deal
India's Laurus Labs hits over 20-mth low after fatal fire at plant